The 20-Year Dismissal
Reports of persistent sexual dysfunction after SSRI discontinuation began appearing in the medical literature in the early 1990s, shortly after fluoxetine (Prozac) became widely prescribed. For over two decades, these reports were systematically dismissed by the medical establishment and pharmaceutical companies.
The dismissal took several forms:
- Attribution to returning depression — Patients reporting sexual symptoms after stopping antidepressants were told their symptoms were a sign that their depression was returning, not a drug effect.
- Psychological attribution — Symptoms were attributed to anxiety, relationship problems, or psychosomatic causes.
- Absence from prescribing information — PSSD was not listed as a potential adverse effect in any SSRI or SNRI prescribing information until the EMA mandate in 2019.
- Lack of diagnostic criteria — Without formal diagnostic criteria, clinicians had no framework for recognising or documenting PSSD.
The Healy et al. 2019 Study: Patients Across 23 Countries
The turning point came with a landmark case series published by Healy et al. in 2019. The study documented 62 patients across 23 countries who had experienced persistent sexual dysfunction after stopping SSRIs or SNRIs. Key findings:
| Finding | Data |
|---|---|
| Patients documented | 62 across 23 countries |
| Majority not believed by doctors | Yes — majority reported dismissal or minimisation |
| Symptoms after short courses | Cases documented after as few as 1–2 doses |
| Duration of symptoms | Months to over a decade |
| Impact on EMA review | Instrumental in triggering the 2019 EMA safety review |
The EMA's 2019 Recognition
In 2019, the European Medicines Agency completed a safety review of SSRIs and SNRIs and concluded that the evidence supported a causal relationship between these medications and persistent sexual dysfunction after discontinuation. The EMA issued a mandate requiring all product information for SSRIs and SNRIs sold in Europe to include PSSD as a potential persistent adverse effect.
This was a watershed moment. For the first time, a major regulatory body had officially acknowledged what patients had been reporting for decades. However, the EMA mandate applied only to European labelling — the FDA has not issued a similar mandate for the United States market as of 2026.
The Pharmaceutical Company Response
Pharmaceutical companies have generally not proactively communicated about PSSD beyond the minimum required by regulatory mandates. The history of PSSD recognition mirrors other drug safety issues where patient reports preceded regulatory action by years or decades — a pattern that has led to calls for improved pharmacovigilance systems that take patient-reported adverse effects more seriously.
Why Awareness Remains Low in Clinical Practice
Even after the EMA's 2019 recognition, awareness of PSSD in clinical practice remains low for several reasons:
- The EMA mandate updated European drug labelling, but most clinicians do not routinely read updated product information for drugs they have been prescribing for years
- PSSD is not included in major psychiatric or primary care guidelines as of 2026
- Medical education has not been updated to include PSSD
- The FDA has not issued a similar mandate, meaning US prescribing information may not include PSSD
According to Shrooomz's research into serotonergic health, this awareness gap is one of the most significant barriers facing PSSD patients — and one of the reasons why patient-led research and advocacy communities have become the primary source of information for many affected individuals.
Explore Shrooomz Botanical Supplements
USA-grown. Third-party tested. Formulated for serotonergic health and neuroplasticity support.
View Our Supplements →Return to the PSSD Resource Hub. Related: What Is PSSD? | Natural Approaches to PSSD | PSSD Recovery Research | Can Psilocybin Help With PSSD?